Acadian Asset Management LLC increased its position in shares of GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 61.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 534,753 shares of the biotechnology company’s stock after purchasing an additional 204,227 shares during the period. Acadian Asset Management LLC owned 0.83% of GlycoMimetics worth $150,000 at the end of the most recent quarter.
Separately, Vanguard Group Inc. boosted its stake in GlycoMimetics by 14.0% during the first quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock worth $8,286,000 after buying an additional 340,112 shares during the period. 75.19% of the stock is owned by institutional investors.
GlycoMimetics Stock Performance
Shares of GLYC opened at $0.16 on Friday. The company’s 50-day simple moving average is $0.20 and its 200-day simple moving average is $0.92. GlycoMimetics, Inc. has a 1 year low of $0.16 and a 1 year high of $3.53. The stock has a market capitalization of $10.62 million, a PE ratio of -0.28 and a beta of 2.07.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on GLYC
Insider Buying and Selling
In other GlycoMimetics news, major shareholder Public Equities L.P. Invus sold 258,335 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $0.24, for a total value of $62,000.40. Following the completion of the transaction, the insider now owns 8,330,729 shares of the company’s stock, valued at approximately $1,999,374.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 911,859 shares of company stock valued at $205,659 in the last ninety days. Company insiders own 8.70% of the company’s stock.
GlycoMimetics Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
See Also
- Five stocks we like better than GlycoMimetics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Does Downgrade Mean in Investing?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Short Selling: How to Short a Stock
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report).
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.